Negative EMA opinion for the ipilimumab/nivolumab combination
Yesterday it was announced that the combination of ipilimumab and [...]
Nivolumab is safe and effective for older kidney cancer patients
Findings from an expanded access programme giving 389 metastatic renal [...]
First-line tivozanib approved for use in NHS Scotland
We are delighted that the Scottish Medicines Consortium (SMC), which reviews [...]
Personalised management of advanced kidney cancer
A recent article published in the 2018 American Society of Clinical [...]
Axitinib for metastatic non-clear cell renal cell carcinoma
Results from a phase 2 clinical trial of axitinib (Inlyta) [...]
An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma
The International Kidney Cancer Coalition (IKCC), of which KCSN is [...]
Avelumab plus axitinib combination effective in the first-line but with unfavourable side effects
Safety results from a phase 1b dose-finding and dose expansion [...]
Implications of real world data on the use of first-line pazopanib for the management of metastatic kidney cancer
The following interview with Dr Eric Jonasch, medical oncologist from MD Anderson Cancer Centre [...]
Treatment of metastatic kidney cancer in older patients
A recent meta-analysis evaluating the efficacy of first- and second-line [...]
Immunotherapy for non-clear cell kidney cancer
The following interview with Dr Eric Jonasch, medical oncologist from [...]
